Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,459 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The hazards of cross comparing the drug toxicity results from different trials in metastatic renal cancer: in response to a letter from Dr. Catalá-López.
Powles T, Sarwar N, Jones R, Wilson P, Boleti E, Protheroe A, Crabb S, Shamash J, Stockdale A, Lim L, Nathan P, Chowdury S. Powles T, et al. Among authors: wilson p. Eur J Cancer. 2013 Mar;49(4):986-7. doi: 10.1016/j.ejca.2012.10.010. Epub 2012 Nov 5. Eur J Cancer. 2013. PMID: 23138000 No abstract available.
A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer.
Powles T, Foreshew SJ, Shamash J, Sarwar N, Crabb S, Sahdev A, Nixon J, Lim L, Pungaliya A, Foreshaw A, Davies R, Greenwood M, Wilson P, Pacey S, Galazi M, Jones R, Chowdhury S. Powles T, et al. Among authors: wilson p. Eur J Cancer. 2014 Aug;50(12):2057-64. doi: 10.1016/j.ejca.2014.04.021. Epub 2014 Jun 4. Eur J Cancer. 2014. PMID: 24908540 Clinical Trial.
Letter to the Editor: Central nervous system relapse rate and dose intensification in poor risk metastatic germ cell tumours-A comment on: 'Patterns of relapse in poor prognosis germ cell tumours in the GETUG-13 trial: Implications for the assessment of brain metastases.' by Loriot and colleagues.
Alifrangis C, Wilson P, Shamash J. Alifrangis C, et al. Among authors: wilson p. Eur J Cancer. 2018 May;95:102-103. doi: 10.1016/j.ejca.2018.01.116. Epub 2018 Mar 31. Eur J Cancer. 2018. PMID: 29615282 No abstract available.
A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol.
Shamash J, Powles T, Sarker SJ, Protheroe A, Mithal N, Mills R, Beard R, Wilson P, Tranter N, O'Brien N, McFaul S, Oliver T. Shamash J, et al. Among authors: wilson p. Br J Cancer. 2011 Feb 15;104(4):620-8. doi: 10.1038/bjc.2011.7. Epub 2011 Feb 1. Br J Cancer. 2011. PMID: 21285990 Free PMC article. Clinical Trial.
5,459 results